Becton, Dickinson Faces Allegations of Stifling Competition in Hernia Mesh Industry
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 22 2025
0mins
Source: SeekingAlpha
Lawsuit Filed: Tela Bio has filed a lawsuit against Becton, Dickinson, alleging anti-competitive practices in the surgical hernia mesh market, specifically targeting its OviTex product.
Allegations of Retaliation: The lawsuit claims Becton, Dickinson retaliated against hospitals for purchasing OviTex and used long-term contracts to limit competition by forcing customers to buy exclusively from them.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 202.38 USD with a low forecast of 183.00 USD and a high forecast of 220.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
3 Buy
5 Hold
0 Sell
Moderate Buy
Current: 203.400
Low
183.00
Averages
202.38
High
220.00
Current: 203.400
Low
183.00
Averages
202.38
High
220.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
